Back

KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney

Ichimura, T.; Mori, Y.; Aschauer, P.; Padmanabha Das, K. M.; Padera, R. F.; Weins, A.; Nasr, M. L.; Bonventre, J. V.

2020-09-18 infectious diseases Community evaluation
10.1101/2020.09.16.20190694 medRxiv
Show abstract

SARS-CoV-2 precipitates respiratory distress by infection of airway epithelial cells and is often accompanied by acute kidney injury. We report that Kidney Injury Molecule-1/T cell immunoglobulin mucin domain 1 (KIM-1/TIM-1) is expressed in lung and kidney epithelial cells in COVID-19 patients and is a receptor for SARS-CoV-2. Human and mouse lung and kidney epithelial cells express KIM-1 and endocytose nanoparticles displaying the SARS-CoV-2 spike protein (virosomes). Uptake was inhibited by anti-KIM-1 antibodies and TW-37, a newly discovered inhibitor of KIM-1-mediated endocytosis. Enhanced KIM-1 expression by human kidney tubuloids increased uptake of virosomes. KIM-1 binds to the SARS-CoV-2 Spike protein in vitro. KIM-1 expressing cells, not expressing angiotensin-converting enzyme 2 (ACE2), are permissive to SARS-CoV-2 infection. Thus, KIM-1 is an alternative receptor to ACE2 for SARS-CoV-2. KIM-1 targeted therapeutics may prevent and/or treat COVID-19.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Clinical Investigation
● 164 papers in training set
Top 0.1%
18.3%
2
Nature Communications
○ 4913 papers in training set
Top 8%
17.2%
3
JCI Insight
● 241 papers in training set
Top 0.6%
6.2%
4
Science Translational Medicine
● 111 papers in training set
Top 0.4%
4.8%
5
Cell Reports Medicine
○ 140 papers in training set
Top 2%
3.5%
50% of probability mass above
6
eLife
● 5422 papers in training set
Top 27%
3.5%
7
Cell Reports
○ 1338 papers in training set
Top 21%
2.0%
8
Journal of Experimental Medicine
● 106 papers in training set
Top 2%
2.0%
9
Cellular & Molecular Immunology
○ 14 papers in training set
Top 0.8%
1.9%
10
Immunity
○ 58 papers in training set
Top 2%
1.9%
11
Science Immunology
● 81 papers in training set
Top 1.0%
1.9%
12
Cell
○ 370 papers in training set
Top 10%
1.9%
13
Science
● 429 papers in training set
Top 13%
1.9%
14
Cell Research
○ 49 papers in training set
Top 1%
1.8%
15
Proceedings of the National Academy of Sciences
● 2130 papers in training set
Top 34%
1.6%
16
Molecular Therapy
○ 71 papers in training set
Top 2%
1.3%
17
Nature Biotechnology
○ 147 papers in training set
Top 5%
1.3%
18
Gastroenterology
○ 40 papers in training set
Top 1%
1.1%
19
Science Advances
● 1098 papers in training set
Top 25%
0.9%
20
Protein & Cell
◐ 25 papers in training set
Top 2%
0.9%
21
ACS Nano
● 99 papers in training set
Top 4%
0.8%
22
Nature Medicine
○ 117 papers in training set
Top 4%
0.8%
23
mBio
● 750 papers in training set
Top 11%
0.7%
24
Med
○ 38 papers in training set
Top 0.9%
0.7%
25
Theranostics
● 33 papers in training set
Top 2%
0.7%
26
Circulation
○ 66 papers in training set
Top 3%
0.6%
27
Nature Immunology
○ 71 papers in training set
Top 2%
0.6%
28
The Journal of Immunology
◐ 146 papers in training set
Top 2%
0.6%
29
Scientific Reports
○ 3102 papers in training set
Top 79%
0.6%
30
PLOS ONE
● 4510 papers in training set
Top 72%
0.6%